Third Harmonic Bio (Third Harmonic Bio) ROC % : -596.57% (As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Third Harmonic Bio ROC %?

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Third Harmonic Bio's annualized return on capital (ROC %) for the quarter that ended in Mar. 2024 was -596.57%.

As of today (2024-05-28), Third Harmonic Bio's WACC % is 10.39%. Third Harmonic Bio's ROC % is -569.13% (calculated using TTM income statement data). Third Harmonic Bio earns returns that do not match up to its cost of capital. It will destroy value as it grows.

Third Harmonic Bio ROC % Historical Data

The historical data trend for Third Harmonic Bio's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Third Harmonic Bio ROC % Chart

Third Harmonic Bio Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

ROC %

-3,280.24

-3,477.40

-926.03

-562.36

Third Harmonic Bio Quarterly Data
	Dec20	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROC %	Get a 7-Day Free Trial								-662.37	-582.36	-550.16	-507.99	-596.57

Third Harmonic Bio ROC % Calculation

Third Harmonic Bio's annualized Return on Capital (ROC %) for the fiscal year that ended in Dec. 2023 is calculated as:

	ROC % (A: Dec. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (A: Dec. 2022 )	+	Invested Capital (A: Dec. 2023 ))	/ count )
=	-43.954 * ( 1 - 0% )	/	( (7.39	+	8.242)	/ 2 )
=	-43.954	/	7.816
=	-562.36 %

where

	Invested Capital		(A: Dec. 2022 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	298.675	-	4.103	-	( 288.877	-	max(0, 5.653	-	292.835	+	288.877	))
=	7.39

	Invested Capital		(A: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	277.711	-	2.441	-	( 269.07	-	max(0, 5.418	-	272.446	+	269.07	))
=	8.242

Third Harmonic Bio's annualized Return on Capital (ROC %) for the quarter that ended in Mar. 2024 is calculated as:

	ROC % (Q: Mar. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2023 )	+	Invested Capital (Q: Mar. 2024 ))	/ count )
=	-45.16 * ( 1 - 0% )	/	( (8.242	+	6.898)	/ 2 )
=	-45.16	/	7.57
=	-596.57 %

where

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	277.711	-	2.441	-	( 269.07	-	max(0, 5.418	-	272.446	+	269.07	))
=	8.242

	Invested Capital		(Q: Mar. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	270.521	-	2.044	-	( 262.826	-	max(0, 4.018	-	265.597	+	262.826	))
=	6.898

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

Third Harmonic Bio (NAS:THRD) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Third Harmonic Bio's WACC % is 10.39%. Third Harmonic Bio's ROC % is -569.13% (calculated using TTM income statement data). Third Harmonic Bio earns returns that do not match up to its cost of capital. It will destroy value as it grows.

Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Third Harmonic Bio ROC % Related Terms

Thank you for viewing the detailed overview of Third Harmonic Bio's ROC % provided by GuruFocus.com. Please click on the following links to see related term pages.

Third Harmonic Bio (Third Harmonic Bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Third Harmonic Bio Inc (NAS:THRD) » Definitions » ROC %

Comparable Companies

Traded in Other Exchanges

N/A

Address

1700 Montgomery Street, Suite 210, San Francisco, CA, USA, 94111

Website

https://www.thirdharmonicbio.com

Third Harmonic Bio Inc is a clinical-stage company focused on the development of the next wave of medicine for the treatment of inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases.. The company's product candidate, THB001, is a selective, oral small-molecule inhibitor of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival.

Executives

Julie Person	officer: Chief Administrative Officer	C/O THIRD HARMONIC BIO, INC., 300 TECHNOLOGY SQUARE, 8TH FLOOR, CAMBRIDGE MA 02139
Edward R. Conner	officer: Chief Medical Officer	501 CANAL BLVD., POINT RICHMOND TECH CENTER, RICHMOND CA 94804
Biotechnology Value Fund L P	other: See Explanation of Responses	44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Partners L P/il	10 percent owner	44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Gp Holdings Llc	other: See Explanation of Responses	44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Ii Gp Llc	other: See Explanation of Responses	44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf I Gp Llc	other: See Explanation of Responses	44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Partners Os Ltd.	other: See Explanation of Responses	P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Biotechnology Value Trading Fund Os Lp	other: See Explanation of Responses	P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Bvf Inc/il	10 percent owner	44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Mark N Lampert	10 percent owner	1 SANSOME ST, 30TH FL, SAN FRANCISCO CA 94104
Biotechnology Value Fund Ii Lp	other: See Explanation of Responses	44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Orbimed Advisors Llc	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
David P Bonita	director, 10 percent owner	C/O ORBIMED ADVISORS LLC, 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Atlas Venture Fund Xi, L.p.	10 percent owner	400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139